Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
AnaptysBio, Inc. Banner

AnaptysBio, Inc.

ANAB Stock Analysis

Page title

Section title

About AnaptysBio, Inc.

Biotechnology
Healthcare

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations...

AnaptysBio, Inc. Key Metrics

Market Cap
$1B
52 Weeks Low
$13.36
52 Weeks High
$41.31
P/B
107.36x
P/E
-6.23x
P/S
38.42x

Upcoming Events

    ANAB Analyst Forecasts

    ‌
    ‌

    ANAB Financials

    ANAB Income Statement Key Metrics

    • Revenue(TTM)30.47 M
    • Gross Profit(TTM)28.08 M
    • EBITDA(TTM)-150.26 M
    • Net Income(TTM)-170.12 M
    • EPS Diluted(TTM)-6.35

    Decode ANAB's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    ANAB earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of ANAB (0.862) is higher than the average of its peers (0.646).

    Net Profit Margin vs Peers

    Net profit margin ratio of ANAB (-9.537) is higher than the average of its peers (-13.962).

    ANAB Return on Equity

    See how efficiently ANAB generates profit for it's shareholders.

    -185.71%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of ANAB (-1.857) is lower than the average of its peers (-0.465).

    Return on Equity Growth

    ANAB's Return on Equity has shown poor growth over the past 10 years, increasing by only -12.16%.

    ANAB Revenue Growth

    See how ANAB has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    ANAB's revenue has shown poor growth over the past 10 years, increasing by only 0.80%.